Tagged with HE

China Hans Schmid, chairman; and Enrico Magnani, GM, of global cancer supportive care leader Helsinn Pharmaceuticals’ operations in China, share the Swiss company’s strategy in China, having entered in 2012; the milestone of launching their first product in China in November 2018 for chemotherapy-induced nausea and vomiting (CINV); the importance they…

Hungary Irma Veberic, general manager of Roche Hungary, gives her insights on the key issues being faced by the Hungarian healthcare system and the company’s role as a partner in improving health outcomes and raising life expectancy in the country. Veberic goes on to highlight the affiliate’s strong contribution to Hungary…

Czech Republic Tomáš Dolezal, president of the International Society for Pharmacoeconomics and Outcomes (ISPOR) Czech Regional Chapter and director of the Institute of Health Economics and Technology Assessment (iHETA), gives an overview of the missions and goals of these two institutes and the pivotal role of health technology assessment (HTA) in the…

Hungary Veronika Ferencz, general manager of Exeltis Hungary, gives an update on the recent activies and achievement of the affiliate since her last PharmaBoardroom interview in 2016. Furthermore, Ferencz goes on to highlight how the upcoming launch of the company’s first innovative product Slinda® is a very significant step in its…

UAE Rahja Daher, head of the Health Group for the Swiss Business Council (SBC) Dubai & Northern Emirates discusses the association’s formation, priorities and major challenges, as well as an outline of the healthcare and life sciences sector in the UAE at large.   Dubai is by far still the hub…

Czech Republic Štěpán Svačina, Chairman of the Czech Medical Association (CzMA), gives insights into the challenges that the Czech Republic faces in bringing change to the life sciences infrastructure. Whilst pointing out the areas in which the country is seeing positive advances — efficient communication with key personalities in healthcare such as…

Hungary Prof. Éva Szökő, president of the Hungarian Society for Pharmaceutical Sciences (MGYT), shares her insights on the activities of the society, its collaboration with institutions and industry players in the area of prevention, adherence, public health awareness, translational research, and its future outlook.   [Hungarian] patients are suspicious of prescribed…

Czech Republic The Czech Republic’s Minister of Health,  Adam Vojtěch, is the youngest in the country’s history and has set out an ambitious reform programme to improve the state of the Czech healthcare system.   In my office, I will actively seek to fulfil the key points of my election program –…

Sweden Key stakeholders in Swedish pharma explain why Sweden’s record on cancer care is the best in Europe and what more still needs to be done.   National investments in cancer care have improved patient outcomes and reduced waiting times Malin Parkler, Pfizer With an estimated 18 million cases globally in…

Hungary Dr. Péter Ofner, Former Director of the Gottsegen Hungarian Insititute of Cardiology, shares his insights on the cardiological capabilities of the institute, the epidemiological profile of the country, the collaborations with industry players, and outlooks for the future of this field as well as the country.   Hungary is a…

Hungary Dr. György Blaskó, former President and Chairman of the Hungarian European Clinical Research Infrastructure Network, explains the role of the research network, the impact it has on the Hungarian clinical research environment, and the areas of improvement moving forward.   Domestic centralized health care and the presence of a single…

China Dr. Zhang Yu, CEO of Aeon Therapeutics, shares the unique journey that motivated him to establish Aeon Therapeutics, as a joint venture of Chinese VcanBio and US-based Eureka Therapeutics, to commercialize Eureka’s assets in China and to tackle one of the biggest challenges facing the global CAR-T industry: the difficulty…